Form 8-K - Current report:
SEC Accession No. 0001193125-23-147097
Filing Date
2023-05-17
Accepted
2023-05-17 17:01:03
Documents
17
Period of Report
2023-05-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d503970d8k.htm   iXBRL 8-K 31520
2 EX-1.1 d503970dex11.htm EX-1.1 204400
3 EX-5.1 d503970dex51.htm EX-5.1 6953
4 EX-99.1 d503970dex991.htm EX-99.1 9161
8 GRAPHIC g503970g0517054629596.jpg GRAPHIC 2334
9 GRAPHIC g503970goodwin.jpg GRAPHIC 8384
  Complete submission text file 0001193125-23-147097.txt   455401

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA akro-20230516.xsd EX-101.SCH 2851
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE akro-20230516_lab.xml EX-101.LAB 17995
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akro-20230516_pre.xml EX-101.PRE 11262
11 EXTRACTED XBRL INSTANCE DOCUMENT d503970d8k_htm.xml XML 3367
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38944 | Film No.: 23932619
SIC: 2834 Pharmaceutical Preparations